

Population-level diversity in the association of genetic polymorphisms of one-carbon metabolism with breast cancer risk

Shaik Mohammad Naushad^{1,2} · Chandrasekhar Divya² · M. Janaki Ramaiah² · Tajamul Hussain³ · Salman A. Alrokayan⁴ · Vijay Kumar Kutala⁵

Received: 10 May 2016 / Accepted: 8 August 2016 / Published online: 19 August 2016
© Springer-Verlag Berlin Heidelberg 2016

Abstract Aberrations in one-carbon metabolism were reported to increase breast cancer risk by influencing the DNA synthesis and methylation of DNA and catecholamines. However, the results of these association studies remain inconclusive. We have explored the contribution of eight genetic polymorphisms in modulating the susceptibility to breast cancer by performing a meta-analysis of worldwide studies. In total, 62 case-control studies representing 17 different populations involving 18,117 breast cancer cases and 23,573 healthy controls were included in this meta-analysis. Out of the eight polymorphisms analyzed, methylenetetrahydrofolate reductase (*MTHFR*) C677T exhibited positive association with the breast cancer risk in both fixed effects (OR 1.14, 95 % CI 1.10–1.17) and random effects (OR 1.10, 95 % CI 1.02–1.18) models. Solute carrier family 19 (folate transporter), member 1 (*SLC19A1*) G80A exhibited positive association (OR 1.16, 95 % CI 1.03–1.31) while *MTR* A2756G exhibited an inverse association (OR 0.78, 95 % CI 0.75–0.82) with the breast in fixed effect model alone. Significant heterogeneity was observed in the association of *MTHFR* C677T with breast cancer even between studies from

the same geographical area, specifically among Chinese, Indians, and Turks. Subgroup analysis revealed *MTHFR* C677T-mediated breast cancer risk in post-menopausal women and women with low dietary intake of folate. Geographical area wise segregation of data revealed *MTHFR*-mediated increased breast cancer risk in populations who consume methionine-rich diet. Altitude-level variations were observed in the association of *SHMT1* C1420T with breast cancer. India and Brazil of same altitude showed an inverse association with this polymorphism, while USA and China that share similar altitude showed a null association. *MTHFR* C677T and *SLC19A1* G80A are the two polymorphisms of one-carbon metabolic pathway that increase breast cancer in the worldwide population. Dietary patterns and altitudinal variations are the likely risk modulators that are contributing toward ethnic- and population-level variations in genetic associations.

Keywords Breast cancer · One-carbon metabolism · Polymorphisms · Altitude

✉ Shaik Mohammad Naushad
naushadsm@gmail.com

¹ Biochemical Genetics, Sandor Life Sciences Pvt Ltd, Banjara Hills, Road No. 3, Hyderabad 500034, India

² School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur 613401, India

³ Center of Excellence in Biotechnology Research, King Saud University, PO Box 2455, Riyadh 11451, Saudi Arabia

⁴ Department of Biochemistry, College of Science, King Saud University, PO Box 2455, Riyadh 11451, Saudi Arabia

⁵ Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad 500082, India

Introduction

The etiology of breast cancer is complex, involving interactions between genetic and environmental factors; and epigenetic modifications. The high-penetrant genetic mutations account for less than 10 % breast cancer cases (Hoskins et al. 1995). Several genetic polymorphisms have been explored across different pathways for possible association with breast cancer (Fachal and Dunning 2015). Among these pathways, the most widely investigated pathway is the one-carbon metabolic pathway, which was so named because of the several metabolic reactions involving the transfer of one-carbon moiety from one substrate to another to form several crucial metabolic precursors.

The dietary folate in the form of folyl polyglutamates is hydrolyzed by folate hydrolase (prostate-specific membrane antigen) 1 (FOLH1) to folyl monoglutamates, which are absorbed easily by the intestinal cells (Halsted 1989). Folate reductase catalyzes the reduction of folate to dihydrofolate (DHF) and tetrahydrofolate (THF). The THF of the blood stream is transported into RBC by the solute carrier family 19 (folate transporter), membrane 1 (SLC19A1) (Brzezińska et al. 2000). The methylene moiety from the serine is transferred to THF to form 5,10-methylene THF in the presence of serine hydroxymethyltransferase 1 (soluble) (SHMT1) (Stover and Schirch 1992). The 5,10-methylene THF is the common substrate for two rate-limiting enzymes, i.e., thymidylate synthase (TYMS) and methylenetetrahydrofolate reductase (NAD(P)H) (MTHFR), which catalyze the conversion of dUMP to dTMP and FAD-dependent reduction of 5,10-methylene THF to 5-methyl THF, respectively (Trinh et al. 2002). The 5-methyl THF is the cosubstrate for the remethylation of homocysteine to methionine in the presence of 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR). The other cosubstrate, i.e., methyl cobalamin is formed due to reductive methylation of cobalamin by the 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR). The MTR-MTRR holoenzyme complex, thus contributes toward the remethylation of homocysteine to methionine (Brot and Weissbach 1966). Methionine is the precursor for the synthesis of *S*-adenosylmethionine (SAM), which is a universal methyl donor that donates a methyl group to DNA, histones, and catecholamines. After donating a methyl group, SAM is converted to *S*-adenosyl homocysteine (SAH).

Since aberrant methylation of tumor suppressors and catechol estrogens, defective DNA synthesis and repair are the well-documented risk factors for breast cancer; several polymorphisms of one-carbon metabolic pathway were explored for the possible association with breast cancer. Limited studies are there on *FOLH1* C1561T polymorphism in association with breast cancer (Mohammad et al. 2011; Naushad et al. 2011). Several other genetic variants of *FOLH1* are also explored for their association with breast cancer (Divyya et al. 2013). *SLC19A1* G80A was shown to exert breast cancer risk in Indian and Brazilian populations (Carvalho Barbosa Rde et al. 2011; Mohammad et al. 2011; Naushad et al. 2011), while no association was reported in the US population (Xu et al. 2007). *SHMT1* C1420T polymorphism was shown to confer protection against breast cancer in Indian (Mohammad et al. 2011; Naushad et al. 2011), Chinese (Wu et al. 2014), and Brazilian (Carvalho Barbosa Rde et al. 2011) populations while null association was observed in the US and (Xu et al. 2007) Taiwanese (Yu et al. 2007) populations. *TYMS* 5'-UTR 28 bp tandem repeat polymorphism showed null association with breast cancer risk in six studies (Xu et al. 2007; Suzuki et al. 2008; Carvalho Barbosa Rde et al. 2011;


Naushad et al. 2011). *TYMS* 3'-UTR ins6/del6 showed positive association with breast cancer in the Japanese population (Zhai et al. 2006), while it showed a null association in Indians (Naushad et al. 2011), Chinese (Zhai et al. 2006) and Germans (Justenhoven et al. 2005). *MTHFR* C677T is the most widely studied polymorphism of this pathway; the segregation of data based on ethnic group or populations revealed a strong association of this polymorphism in Turkey (Deligezer et al. 2005; Ozen et al. 2013), China (Cheng et al. 2008; Gao et al. 2009; Wu et al. 2012; Jiang-Hua et al. 2014), Syria (Lajin et al. 2012), Morocco (Diakite et al. 2012), and North America (Maruti et al. 2009; Bentley et al. 2010; Ramos-Silva et al. 2015). Two studies, i.e., one on multi-ethnic group (Le Marchand et al. 2004) and another on the Iranian population (Hosseini et al. 2011), showed a protective role of this polymorphism. In rest of the population ($N = 10$), the association of this polymorphism was either borderline or null (Shrubsole et al. 2004; Lee et al. 2004; Inoue et al. 2008; Ma et al. 2009; Hosseini et al. 2011; Prasad and Wilkhoo 2011; Akram et al. 2012; Awwad et al. 2015). *MTR* A2756G was investigated in ten different populations out of which it was identified as a risk factor in Iranian (Hosseini 2013) and Australian (Beetstra et al. 2008) populations. In two populations, i.e., Greece (Kakkoura et al. 2015) and China (He et al. 2014), this polymorphism showed an inverse association with breast cancer risk while in other population, it showed a null association (Platek et al. 2009; Weiwei et al. 2014; He et al. 2014). *MTRR* A66G was identified as a risk for breast cancer in a Russian population (Tao et al. 2009), while it was shown to have an inverse association with Thai (Sangrajrang et al. 2009; Sangrajrang et al. 2010) and Australian (Beetstra et al. 2008) populations. In another eight populations, *MTRR* A66G showed a null association (Kotsopoulos et al. 2008; Burcoş et al. 2010; Weiner et al. 2012).

The variations in genetic association across different populations might be attributed to gene-gene and gene-nutrient interactions which act as potential risk modulators. In the current study, we have aimed to provide a comprehensive overview of all the genetic association relevant to one-carbon metabolism as possible risk modulators for breast cancer using meta-analysis approach. This will help in identifying the genetic risk factors that are common across the different populations and also to emphasize the role of dietary and lifestyle patterns in dictating the breast cancer risk along with a given set of polymorphisms.

Materials and methods

Search strategy and selection criteria

We searched four electronic databases (PubMed, Google Scholar, Scopus, and Medline) to identify eligible studies that



Flowchart 1 Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram. This illustrates the selection process of the studies

were published before December 2015. Articles were retrieved by using the following keywords: “GCPII/FOLH1,” “RFC1/SLC19A1,” “SHMT1,” “TYMS,” “MTHFR,” “MTR,” “MTRR,” “polymorphism,” and “breast cancer.” The reference list of the retrieved publications was also reviewed to identify additional relevant articles.

Inclusion and exclusion criteria

The inclusion criteria were the following: (a) case-control study involving unrelated individuals, (b) information on the

raw data of genotypes, (c) information on ethnicity, and (d) the genotype distribution in accordance with Hardy-Weinberg equilibrium (HWE). The exclusion criteria were the following: (a) case only study, (b) meta-analysis, (c) only minor allele frequencies provided, and (d) duplication of data.

Data extraction

A standardized form was used by the investigators for independent extraction of data and for credibility of results. The following information was extracted from each published

Table 1 Association of polymorphisms of one-carbon metabolic pathway with breast cancer risk

Polymorphism	Number of populations (subjects)	Pooled odds ratio		Test for homogeneity	Bias
		Fixed effects	Random effects		
FOLH1 C1561T (rs61886492) T vs. C-allele	1 (486)	0.74 (0.46–1.19)	ND	ND	ND
SLC19A1 G80A (rs1051266) A vs. G-allele	3 (3177)	1.16 (1.03–1.30) ^a	1.28 (0.98–1.67)	7.91 ^a	4.78
cSHMT C1420T (rs1979277) T vs. C-allele	4 (5742)	0.93 (0.86–1.01)	0.86 (0.71–1.03)	7.94 ^a	–2.15
TYMS 5'-UTR 2R/3R (rs45445694) 2R vs. 3R	5 (5461)	0.96 (0.88–1.04)	0.96 (0.88–1.04)	2.76	2.24 ^a
TYMS 3'-UTR ins6/del6 Del6 vs. ins6-allele	4 (2676)	1.02 (0.91–1.14)	1.16 (0.84–1.59)	19.06 ^a	5.19
MTHFR C677T (rs1801133) T vs. C-allele	17 (51,690)	1.14 (1.10–1.17) ^a	1.10 (1.02–1.18) ^a	57.88 ^a	–0.73
MTR A2756G (rs1805087) G vs. A-allele	10 (22,584)	0.78 (0.75–0.82) ^a	0.99 (0.76–1.29)	236.06 ^a	6.28 ^a
MTRR A66G (rs1801394) G vs. A-allele	11 (15,018)	1.02 (0.97–1.07)	1.02 (0.95–1.09)	15.78	–0.97

This table illustrates association of each folate pathway genetic polymorphism with breast cancer risk in the worldwide population. The data from the literature was grouped based on the populations. The number of populations and the number of subjects included for the analysis were depicted

ND not determined

^a Statistically significant




Fig. 1 Association of SLC19A1 G80A with breast cancer in three populations. This illustrates population based risk association in **a** fixed effects model and **b** random effects model

article: first author, year of publication, ethnicity (country), number of cases, number of controls, source of controls, and genotype distribution.

Segregation of data into ethnic groups and populations

The studies from the same ethnic group or population were pooled together to assess ethnicity or population-based risk. This analysis is useful in addressing the risk modulation based on specific dietary or lifestyle patterns. The number of ethnic groups, number of subjects in each group, and their association with each polymorphism were tabulated.

In silico analysis


In order to elucidate the structural and functional effects of the amino acid substitution, Polymorphism Phenotyping v2 (PolyPhen-2) (<http://genetics.bwh.harvard.edu/pph2/>) was

used, which was based on the physical and comparative considerations. The score classifies the proteins into benign, partially damaging and highly damaging.

Statistical analysis

Using statpages.org, chi-square goodness of fit for each cases and control studies was calculated. *p* Value with 95 % confidence interval, odds ratio, and phi coefficient were included in the data. *p* Value with 0.05 or less was considered as significant, and breast cancer risk was assessed through OR. A computational tool (statdirect) was used to conduct meta-analysis of all the studies related to polymorphisms of one-carbon metabolism. The data were computed in the form of number of variant alleles and number of total alleles in cases and controls. The fixed effect model was generated using the Mantel-Haenszel and the Robins-Breslow-Greenland algorithm. These were based on conditional maximum likelihood. The

Fig. 2 Association of SHMT1 C1420T with breast cancer in four populations. This illustrates population based risk association in **a** fixed effects model and **b** random effects model



random effects model was based on the DerSimonian-Laird algorithm. Non-combinability of studies was assessed based on the Cochran’s Q test. The effect of heterogeneity was quantified with the I^2 test. Publication bias was assessed based on the Horbold-Egger test.

Results

Characteristics of the included studies

According to search, 94 potentially relevant articles were identified. After applying the inclusion and exclusion criteria, we have chosen 62 published studies representing 17 populations involving 18,117 cases of breast cancer and 23,573 healthy controls (Flowchart 1).

Meta-analysis databases

There are three studies from India on *FOLHI* C1561T polymorphism where one study was taken as representative which shows no association of this polymorphism with breast cancer (OR 0.74, 95 % CI 0.46–1.19) (Table 1). No other population-specific data were available on *FOLHI* C1561T with relevance to breast cancer.

The data on *SLC19A1* G80A was compiled into three distinct populations, out of which Indian (OR 1.33, 95 % CI 1.02–1.74) and Brazilian (OR 1.63, 95 % CI 1.18–2.28) populations exhibited an increased risk for breast cancer. Null association was observed in US population (OR 1.04, 95 % CI 0.90–1.20). The pooled OR was significant in the fixed effect model (OR 1.16, 95 % CI 1.03–1.30). However, the random effects model showed no statistical significance ($p = 0.08$). Cochran’s Q tests showed evidence of heterogeneity in association ($p = 0.02$). There is no evidence of publication bias ($p = 0.07$) (Fig. 1).

Studies on *SHMT1* C1420T were segregated into four populations; out of these Indian (OR 0.75, 95 % CI 0.58, 0.97) and Brazilian (OR 0.64, 95 % CI 0.44–0.94) populations showed statistically significant protective role against breast cancer. Null association was observed in Chinese (OR 0.97, 95 % CI 0.73–1.29) and US (OR 0.97, 95 % CI 0.89–1.07) populations. Pooled OR was not statistically significant in both fixed effects and random effects models. The Cochran’s Q test of heterogeneity was positive ($p = 0.047$). However, there is no evidence of publication bias ($p = 0.20$) (Fig. 2). Altitudinal variation was observed in the association of *SHMT1* C1420T with breast cancer (Fig. 3).

Studies on *TYMS* 5’UTR 28 bp repeat polymorphism were segregated into five populations, i.e., Chinese, Brazilian, US, Indian, and Japanese. Null association was observed in all the populations. Both fixed effects and random effects models showed null association with pooled data ($p = 0.28$). No evidence of heterogeneity was shown in Cochran’s Q test ($p = 0.60$). There was evidence for publication bias based on Horbold-Egger test ($p = 0.02$).

In four populations, the association of *TYMS* 3’UTR with breast cancer was investigated. Japanese population alone showed statistically significant risk with this polymorphism (OR 3.54, 95 % CI 1.86–6.76). However, the sample size of the study was very less. In other populations, i.e., Indian, Chinese, and Germans, null associations were observed with this polymorphism. Both fixed effects ($p = 0.77$) and random effects ($p = 0.36$) models showed null association of the pooled data. The Cochran’s Q test ($p = 0.0003$) showed evidence of heterogeneity in association. No publication bias was observed for this polymorphism ($p = 0.20$).

As shown in Table 2, the association of *MTHFR* C677T with breast cancer exhibits lot of heterogeneity across different studies. The Cochran’s Q test ($Q 239.09, p < 0.0001$) confirms this heterogeneity. Furthermore, the data was grouped based on




Fig. 3 Influence of altitude on SHMT1 C1420T association. The two population, i.e., Indians and Brazilians who showed protective role (light gray) and two other population, Chinese and US, who showed null association (dark gray) shared similar altitude

Table 2 Association of MTHFR C677T with breast cancer risk across different studies

Author	MTHFR 677 T-allele frequency		OR	95 % CI	
	Cases	Controls		Limit	Limit
Kalyan	0.5698	0.4536	1.5892	0.9785	2.581
Mir	0.2727	0.5614	0.3084	0.1158	0.8214
Naushad	0.6139	0.4869	1.6676	1.0959	2.5376
Prasad	0.4118	0.5132	0.6777	0.2612	1.7584
Barbosa	0.4906	0.52	0.8894	0.6482	1.2205
Ma	0.4938	0.5028	0.9648	0.7912	1.1765
Xu	0.5105	0.478	1.1386	1.0075	1.2868
Bentley	0.439	0.43	1.0371	0.918	1.1717
Platek	0.3568	0.3548	1.0088	0.899	1.1321
Tao	0.2191	0.2218	0.9847	0.8519	1.1381
Chen	0.5105	0.478	1.1386	1.0075	1.2868
Maruti	0.3615	0.3137	1.2389	1.0148	1.5125
Jin	0.2989	0.2872	1.0639	0.6136	1.8447
Yu	0.2199	0.201	1.1238	0.8071	1.5649
Liu	0.5082	0.4973	1.0443	0.8396	1.2989
Cheng	0.3916	0.3992	0.9691	0.7839	1.1981
Gao	0.5305	0.4791	1.2286	1.0471	1.4416
Wu	0.4348	0.4696	0.8777	0.3622	2.1267
Weiwei	0.5539	0.469	1.4044	1.0904	1.809
Jiang-Hua	0.5063	0.4127	1.4595	1.2301	1.7315
He	0.5	0.427	1.3418	1.0646	1.691
Wu	0.6039	0.4036	2.2411	1.4345	3.5013
Li	0.3978	0.2879	1.6362	1.0148	2.6381
Yuan	0.6039	0.4036	2.2411	1.4345	3.5013
Qi	0.5359	0.4574	1.3689	1.0484	1.7874
Shrubsole	0.4873	0.491	0.9855	0.8758	1.1089
Kan	0.6083	0.5268	1.3905	0.9109	2.1224
Hua	0.4432	0.5355	0.6926	0.429	1.1182
Lin	0.2122	0.2016	1.0711	0.7451	1.5397
Chou	0.3187	0.3391	0.9134	0.6723	1.241
Yu	0.2466	0.2112	1.2253	0.8936	1.6802
Justenhoven	0.4599	0.4908	0.8837	0.7482	1.0438
Reljic	0.5962	0.5849	1.0454	0.6498	1.6818
kalemi	0.4545	0.45	1.0196	0.5598	1.857
Deligezer	0.5158	0.4378	1.3671	1.0043	1.861
Ozen	0.4828	0.2891	2.289	1.285	4.0775
Ergul	0.4032	0.3693	1.1551	0.8133	1.6405
Hekim	0.3704	0.3704	1.0067	0.535	1.8944
Cam	0.5814	0.516	1.2996	0.8544	1.9768
Akram	0.5	0.5	1	0.6648	1.5042
Grieu	0.352	0.389	0.8539	0.693	1.0522
Campbell	0.623	0.574	1.2248	0.9493	1.5802
Beetstra	0.56	0.4211	1.724	0.6782	4.3826
Awward	0.544	0.4902	1.2389	0.8737	1.7569
Lee	0.5839	0.5408	1.1907	0.8722	1.6253
Le Marchand	0.3965	0.4628	0.7632	0.6165	0.9447
Inoue	0.3418	0.3714	0.8797	0.7096	1.0905
Suzuki	0.3511	0.3208	1.1459	0.9749	1.3468

Table 2 (continued)


Author	MTHFR 677 T-allele frequency		OR	95 % CI	
	Cases	Controls		Limit	Limit
Alshatwi	0.5093	0.4937	1.064	0.7142	1.5852
Sangrajrang	0.551	0.5338	1.0713	0.8365	1.3719
Hosseini	0.4444	0.5185	0.7434	0.5818	0.9497
Lajin	0.5698	0.4403	1.6797	1.1563	2.4401
Liu	0.5364	0.4755	1.276	1.0532	1.5459
Diakite	0.5339	0.4188	1.5859	1.0366	2.4262
Batschauer	0.4272	0.48	0.8084	0.5014	1.3035
Cortes	0.4256	0.3324	1.4868	1.0663	2.0732
Silva	0.6531	0.5627	1.4613	1.1872	1.7988
Maria	0.4947	0.4698	1.1049	0.98	1.2456
Ericson	0.3571	0.3232	1.1642	0.9422	1.4384
[Combined]					
Fixed			1.1031	1.0707	1.1364
Random			1.1333	1.0734	1.1966

populations. It was identified as a risk factor in North America, Turkey, China, Morocco, and Syria. In other populations, the association was not statistically significant. Both fixed effects ($p < 0.0001$) and random effects ($p = 0.01$) models showed significant risk for this polymorphism in the pooled analysis. The Cochran’s Q test ($p < 0.0001$) indicated heterogeneity in the association across different populations. No evidence of publication bias was observed ($p = 0.34$) (Fig. 4). Except for North America and China, all other countries showing *MTHFR*-mediated risk for breast cancer belong to Mediterranean origin (Fig. 5). As shown in Table 3, even within a geographical area, heterogeneity was observed with regard to association of MTHFR C677T with breast cancer, specifically among Chinese, Indians, and Turks. Subgroup analysis revealed

MTHFR C677T-mediated breast cancer risk in post-menopausal women and in women with low dietary intake of folate (Tables 4 and 5).

Out of the ten populations investigated for possible association of *MTR* A2756G with breast cancer, the Iranian and Australian populations showed positive association; the Chinese and Greece populations showed an inverse association; and the Russian, German, Japanese, Brazilian, Indian, and US populations showed a null association. The pooled data showed the protective role of this polymorphism in fixed effects models alone ($p < 0.0001$). However, the random effects model showed a null association ($p = 0.96$). The Cochran’s Q test ($p < 0.0001$) showed evidence of heterogeneity. There is evidence of publication bias ($p = 0.04$).

Fig. 4 Association of MTHFR C677T with breast cancer across 17 populations. This illustrates population based risk association in **a** fixed effects model and **b** random effects model






Fig. 5 Influence of altitude on *MTHFR* C677T association. Iran, Singapore, Germany, Brazil, and Australia showed odds ratio ≤ 1.01 . Saudi Arabia, Thailand, Greece, and North America showed odds ratios between 1.06 and 1.13. India, Korea, Chinese, Jordan, and Pakistan showed odds ratios between 1.17 and 1.27. Japan, Turkey, Morocco, and Syria showed odds ratios between 1.35 and 1.68. The change in odds ratio was depicted in *gray to black gradation* in the world map

Eleven studies explored the association of *MTRR* A66G with breast cancer. Out of these, only Russian population showed increased risk for breast cancer. Australian population showed an inverse association with breast cancer. Other nine populations, namely Chinese, Romanian, Canadian, Syrian, Polish, Thai, Japanese, and Indian showed a null association. Both fixed effects ($p = 0.41$) and random effects models ($p = 0.59$) showed a null association. The Cochran's Q test ($p < 0.11$) showed no evidence of heterogeneity in association. No publication bias was observed ($p = 0.26$).

As shown in Fig. 6, *in silico* studies revealed the potential damaging effects of *SLC19A1* G80A, *MTHFR* C677T, and *MTRR* A66G, while no damage was observed with *SHMT1* C1420T and *MTR* A2756G polymorphisms (Fig. 6).

Discussion

The current study attempts to investigate the role of putative genetic polymorphisms in one-carbon metabolic pathway with the etiology of breast cancer. Here, we have pooled the data from different ethnic groups and populations. Two polymorphisms, i.e., *SLC19A1* G80A and *MTHFR* C677T, were identified as potential risk factors for breast cancer in the

Table 3 Test for homogeneity between the studies on *MTHFR* C677T segregated based on geographical area

Country	Total number of studies	Cochran's Q	<i>p</i> value
China	15	84.21	<0.0001*
USA	6	7.79	0.17
Turkey	6	12.54	0.03*
India	4	9.07	0.03*
Taiwan	3	1.93	0.38
Australia	3	1.03	0.60
Brazil	3	0.43	0.81

*Denotes statistical significance and indicative of heterogeneity in association

pooled analysis. *SHMT1* C1420T and *MTR* A2756G showed borderline protective role against breast cancer.

The functional analysis revealed the strong association of *SLC19A1* G80A and *MTHFR* C677T polymorphisms with structural instability and damage of the respective proteins. *MTHFR* C677T was shown to induce thermolability in *MTHFR* protein, resulting in its dissociation into inactive monomers with loss of FAD-binding capacity (Yamada et al. 2001). The *SHMT1* C1420T polymorphism has no deleterious effect on *SHMT1* protein. The *MTR* A2756G was shown to induce benign damage to the protein. The *MTRR* A66G showed a deleterious effect on *MTRR* protein. Since *MTR* and *MTRR* act together in 1:1 stoichiometric ratio to form holoenzyme complex (Yamada et al. 2006), it is likely that *MTR* and *MTRR* variant alleles act in synergy in modulating breast cancer risk.

The *SLC19A1* G80A was found to be a risk factor in Indians and Brazilians, but not in US population. This lack of association with US population can be attributed to folate fortification program in the USA. *SLC19A1* expression was reported to be downregulated in conditions of folate deprivation (Ifergan et al. 2008) suggesting that availability of folate might act as an effect modifier. Decreased transcription and altered function might have deleterious impact, thus influencing intracellular folate levels.

The *MTHFR* C677T polymorphism was found to be a risk factor in Mediterranean populations. The risk is probably attributed to change in the dietary patterns from the conventional Mediterranean diet to the processed food resulting in the deficiency of folate and other vitamins (Castro-Quezada et al. 2014). This hypothesis was substantiated by the subgroup analysis showing *MTHFR* C677T-mediated breast cancer risk among women with low folate intake. Our results corroborate with a previous study, which demonstrated increased risk for post-menopausal breast cancer in carriers of *MTHFR* 677 T-allele despite having high plasma folate levels (Ericson et al. 2009). Methionine after the synthesis of SAM and its utilization as a methyl group donor forms SAH and thus contributes toward higher homocysteine levels. The remethylation of homocysteine depends on the bioavailability 5-methyl THF and the activity of *MTR* and *MTRR* complex. The *MTR-MTRR* complex requires methyl cobalamine as cofactor. Thus, the synthesis of 5-methyl THF is hampered in subjects harboring the variants. The other possible contributors for the population level variation in the association are complex interactions among *MTR*, *MTHFR*, and *MTRR*.

The induction of futile folate cycle by *SHMT1*C1420T might be contributing toward the maintenance of one-carbon homeostasis through formation of 5-formyl THF from 5,10-methylene THF (Stover and Schirch 1992) thus conferring protection against breast cancer. In a previous study, we have observed higher circulating folate levels in a subject with

Table 4 Effect of folate in modulating MTHFR C677T-mediated breast cancer risk

Author	MTHFR T-allele freq		OR	95 % CI	
	Cases	Control		Limit	Limit
High folate					
Shrubsole	0.4071	0.4274	0.9202	0.7708	1.0985
Lee	0.3487	0.3333	1.0708	0.7376	1.5545
Maruti	0.3447	0.3212	1.113	0.8183	1.514
Ma	0.2724	0.3344	0.7457	0.5846	0.9511
Suzuki	0.4314	0.3909	1.1824	0.9644	1.4496
Naushad	0.1409	0.0461	3.3184	1.7081	6.4468
Kakkoura	0.3981	0.4035	0.9779	0.8241	1.1605
He	0.295	0.2896	1.0276	0.6859	1.5395
Weiwei	0.2717	0.2382	1.1929	0.8229	1.7294
Chou	0.1818	0.2411	0.7071	0.4221	1.1845
Chen	0.3911	0.3821	1.0383	0.8755	1.2314
Le Marchand	0.3243	0.3295	0.977	0.7912	1.2064
[Combined]					
Fixed			1.0046	0.9362	1.078
Random			1.0098	0.9372	1.088
Low folate					
Shrubsole	0.4312	0.4051	1.113	0.9375	1.3214
Lee	0.3358	0.3333	0.9992	0.4835	2.0652
Maruti	0.3854	0.3066	1.4177	1.0631	1.8906
Ma	0.2841	0.2451	1.2204	0.862	1.7279
Suzuki	0.4235	0.404	1.0843	0.8283	1.4193
Naushad	0.125	0.0865	1.488	0.827	2.6775
Kakkoura	0.435	0.3845	1.2324	1.0397	1.4607
He	0.3303	0.2787	1.2739	0.7285	2.2275
Weiwei	0.3412	0.25	1.5492	1.0879	2.2061
Chou	0.1053	0.2028	0.4722	0.2628	0.8484
Chen	0.4167	0.3581	1.2799	1.0708	1.5298
Le Marchand	0.3177	0.3025	1.0743	0.8625	1.338
[Combined]					
Fixed			1.1907	1.1037	1.2845
Random			1.1877	1.0722	1.3158

SHMT1 TT genotype when compared to those with *SHMT1* CT and CC genotypes (Naushad et al. 2011). The in silico study showing active enzyme in the presence of this polymorphism supports this hypothesis further.

The results of our meta-analysis corroborated with other meta-analyses (Yu and Chen 2012; Liang et al. 2013; Castro-Quezada et al. 2014); (Li et al. 2014a; Rai 2014; Pooja et al. 2015; Kumar et al. 2015) in showing *MTHFR* C677T as a risk factor for breast cancer. The null association of *MTR* A2756G in random effects model and an inverse association with breast cancer in Caucasians were consistent with the meta-analysis of Zhong et al. (2013). The null association of *MTRR* A66G with breast cancer is in agreement

Table 5 Effect of menopausal status on MTHFR C677T-mediated breast cancer risk

Author	MTHFR T-allele freq		OR	95 % CI	
	Cases	Control		Limit	Limit
Pre-menopausal					
Diakite	0.3387	0.2705	1.3763	0.7999	2.3682
Deligezer	0.2611	0.227	1.2053	0.7824	1.857
Le Marchand	0.3129	0.3038	1.046	0.777	1.408
Naushad	0.1348	0.0714	1.9703	0.9701	4.0016
Suzuki	0.3958	0.412	0.9355	0.7392	1.1838
Platek	0.3431	0.3522	0.9613	0.7742	1.1937
Ericson	0.2982	0.3202	0.9035	0.708	1.153
Ma	0.2908	0.2899	1.0037	0.7255	1.3887
[Combined]					
Fixed			1.0026	0.9011	1.1155
Random			1.0026	0.9011	1.1155
Post-menopausal					
Diakite	0.3088	0.1964	1.8206	0.9154	3.6208
Maruti	0.3632	0.3153	1.2389	1.0148	1.5125
Stevens	0.1921	0.1582	1.2641	1.0014	1.5958
Deligezer	0.3384	0.2683	1.39	0.8845	2.1843
Ziva Cerne	0.3467	0.368	0.9111	0.7338	1.1313
Le Marchand	0.3183	0.3116	1.0316	0.9122	1.1665
Naushad	0.1013	0.0597	1.7551	1.0317	2.9857
Suzuki	0.4559	0.3784	1.3761	1.1014	1.7192
Platek	0.3444	0.3284	1.0746	0.9371	1.2324
Ericson	0.2518	0.2158	1.2238	0.9666	1.5495
Ma	0.312	0.3235	0.9486	0.7382	1.2189
[Combined]					
Fixed			1.1177	1.0491	1.1909
Random			1.1494	1.0443	1.265


with the meta-analysis of Hu et al. (2010). To date, there is no other meta-analysis that explored the association of *SLC19A1* G80A with breast cancer risk.

Our study showed agreement with another study (Li et al. 2014b) in demonstrating the protective role of *SHMT1* C1420T against breast cancer in Asians, while null association in Caucasians. In contrast with Wang et al. (2010), we have performed a meta-analysis of *TYMS* polymorphisms based on alleles. And hence, null association was observed. Only Japanese population exhibited positive association of *TYMS* 3'UTR ins6/del6 with breast cancer.

The limitations of the current study were the following: (i) inclusion of only published studies in the current meta-analysis and (ii) this meta-analysis was based on unadjusted odds ratios as it is difficult to retrieve information on the confounding factors from each study.

To summarize, *MTHFR* C677T and *SLC19A1* G80A are considered to be a significant risk factors for breast cancer

Fig. 6 In silico analysis of functional relevance of genetic polymorphisms. PolyPhen-based computational analysis was carried out to elucidate effect of SNPs on the respective proteins. The damage is represented in the form of color gradient from *light gray* to *black* suggesting no damage to severe damage



globally. The *SHMT1* C1420T seems to confer borderline protective role. The ethnic and population level variations in genetic association could be due to gene-gene interaction, gene-nutrient interaction, and genome-epigenome interactions.

Acknowledgments This study is funded by Prof.T.Rajagopalan Research Fund conferred upon MJR.

Compliance with ethical standards

Ethical approval This article does not contain any studies with human participants performed by any of the authors.

Conflict of interest The authors declare that they have no conflict of interest.

References

- Akram M, Malik FA, Kayani MA (2012) Mutational analysis of the MTHFR gene in breast cancer patients of Pakistani population. *Asian Pac J Cancer Prev* 13:1599–1603
- Awwad N, Yousef A-M, Abuhaliema A et al (2015) Relationship between genetic polymorphisms in MTHFR (C677T, A1298C and their Haplotypes) and the incidence of breast cancer among Jordanian females—case-control study. *Asian Pac J Cancer Prev* 16:5007–5011
- Beetstra S, Suthers G, Dhillon V et al (2008) Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer. *Cancer Epidemiol Biomarkers Prev* 17:2565–2571
- Bentley AR, Raiszadeh F, Stover PJ et al (2010) No association between cSHMT genotypes and the risk of breast cancer in the Nurses' Health Study. *Eur J Clin Nutr* 64:108–110
- Brot N, Weissbach H (1966) The role of cobamides in methionine synthesis. Enzymatic formation of holoenzyme. *J Biol Chem* 241(9):2024–8
- Brzezińska A, Wińska P, Balińska M (2000) Cellular aspects of folate and antifolate membrane transport. *Acta Biochim Pol* 47(3):735–749
- Burcoş T, Toma M, Stavarachi M et al (2010) MTRR polymorphism and the risk for colorectal and breast cancer in Romanian patients—a preliminary study. *Chirurgia* 105:379–382
- Carvalho Barbosa Rde C, De Cássia Carvalho Barbosa R, Menezes DC et al (2011) Associations of polymorphisms of folate cycle enzymes and risk of breast cancer in a Brazilian population are age dependent. *Mol Biol Rep* 39:4899–4907
- Castro-Quezada I, Itandehui C-Q, Blanca R-V, Lluís S-M (2014) The Mediterranean diet and nutritional adequacy: a review. *Nutrients* 6: 231–248
- Cheng C-W, Yu J-C, Huang C-S et al (2008) Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan. *Breast Cancer Res Treat* 111: 145–155
- Deligezer U, Akisik EE, Dalay N (2005) Homozygosity at the C677T of the MTHFR gene is associated with increased breast cancer risk in the Turkish population. *In Vivo* 19:889–893
- Diakite B, Tazzite A, Hamzi K et al (2012) Methylenetetrahydrofolate reductase C677T polymorphism and breast cancer risk in Moroccan women. *Afr Health Sci* 12:204–209

- Divyya S, Shree D, Naushad SM et al (2013) Association of glutamate carboxypeptidase II (GCP II) haplotypes with breast and prostate cancer risk. *Gene* 516:76–81
- Ericson UC, Ivarsson MI, Sonestedt E et al (2009) Increased breast cancer risk at high plasma folate concentrations among women with the MTHFR 677T allele. *Am J Clin Nutr* 90(5):1380–1389
- Fachal L, Dunning AM (2015) From candidate gene studies to GWAS and post-GWAS analyses in breast cancer. *Curr Opin Genet Dev* 30:32–41
- Gao C-M, Tang J-H, Cao H-X et al (2009) MTHFR polymorphisms, dietary folate intake and breast cancer risk in Chinese women. *J Hum Genet* 54:414–418
- Halsted CH (1989) The intestinal absorption of dietary folates in health and disease. *J Am Coll Nutr* 8(6):650–658
- He JM, Pu YD, Wu YJ et al (2014) Association between dietary intake of folate and MTHFR and MTR genotype with risk of breast cancer. *Genet Mol Res* 13:8925–8931
- Hoskins KF, Stopfer JE, Calzone KA et al (1995) Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. *JAMA* 273(7):577–585
- Hosseini M (2013) Role of polymorphism of methyltetrahydrofolate-homocysteine methyltransferase (MTR) A2756G and breast cancer risk. *Pol J Pathol* 64:191–195
- Hosseini M, Mojgan H, Massoud H, Ahmad E (2011) MTHFR polymorphisms and breast cancer risk. *Arch Med Sci* 1:134–137
- Hu J, Jia H, Guo-Wu Z et al (2010) MTRR A66G polymorphism and breast cancer risk: a meta-analysis. *Breast Cancer Res Treat* 124:779–784
- Ifergan I, Jansen G, Assaraf YG (2008) The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis. *J Biol Chem* 283:20687–20695
- Inoue M, Robien K, Wang R et al (2008) Green tea intake, MTHFR/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study. *Carcinogenesis* 29:1967–1972
- Jiang-Hua Q, De-Chuang J, Zhen-Duo L et al (2014) Association of methylenetetrahydrofolate reductase and methionine synthase polymorphisms with breast cancer risk and interaction with folate, vitamin B6, and vitamin B 12 intakes. *Tumour Biol* 35:11895–11901
- Justenhoven C, Hamann U, Pierl CB et al (2005) One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany. *Cancer Epidemiol Biomarkers Prev* 14:3015–3018
- Kakkoura MG, Demetriou CA, Loizidou MA et al (2015) Single-nucleotide polymorphisms in one-carbon metabolism genes, Mediterranean diet and breast cancer risk: a case-control study in the Greek-Cypriot female population. *Genes Nutr* 10:453
- Kotsopoulos J, Joanne K, Zhang WW et al (2008) Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer. *Breast Cancer Res Treat* 112:585–593
- Kumar P, Yadav U, Rai V (2015) Methylenetetrahydrofolate reductase gene C677T polymorphism and breast cancer risk: evidence for genetic susceptibility. *Meta Gene* 6:72–84
- Lajin B, Alhaj Sakur A, Ghabreau L, Alachkar A (2012) Association of polymorphisms in one-carbon metabolizing genes with breast cancer risk in Syrian women. *Tumour Biol* 33:1133–1139
- Lee S-A, Kang D, Nishio H et al (2004) Methylenetetrahydrofolate reductase polymorphism, diet, and breast cancer in Korean women. *Exp Mol Med* 36:116–121
- Le Marchand L, Haiman CA, Wilkens LR et al (2004) MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study. *Cancer Epidemiol Biomarkers Prev* 13:2071–2077
- Liang H, Hongjie L, Yulan Y et al (2013) Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk in Chinese population: a meta-analysis of 22 case-control studies. *Tumor Biol* 35:1695–1701
- Li K, Kai L, Wusheng L, Xi D (2014a) Association of 677 C > T (rs1801133) and 1298 A > C (rs1801131) Polymorphisms in the MTHFR gene and breast cancer susceptibility: a meta-analysis based on 57 individual studies. *PLoS One* 9:e71290
- Li L, Ma Y, Jin C et al (2014b) Polymorphism of cytosolic serine hydroxymethyltransferase and breast cancer risk: evidence from a meta-analysis. *Tumour Biol* 35:7361–7367
- Ma E, Iwasaki M, Junko I et al (2009) Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Brazilian women. *BMC Cancer* 9:122
- Maruti SS, Ulrich CM, Jupe ER, White E (2009) MTHFR C677T and postmenopausal breast cancer risk by intakes of one-carbon metabolism nutrients: a nested case-control study. *Breast Cancer Res* 11:R91
- Mohammad NS, Yedluri R, Addepalli P et al (2011) Aberrations in one-carbon metabolism induce oxidative DNA damage in sporadic breast cancer. *Mol Cell Biochem* 349:159–167
- Naushad SM, Pavani A, Digumarti RR et al (2011) Epistatic interactions between loci of one-carbon metabolism modulate susceptibility to breast cancer. *Mol Biol Rep* 38:4893–4901
- Ozen F, Erdis E, Sik E et al (2013) Germ-line MTHFR C677T, FV H1299R and PAI-1 5G/4G variations in breast carcinoma. *Asian Pac J Cancer Prev* 14:2903–2908
- Platek ME, Shields PG, Marian C et al (2009) Alcohol consumption and genetic variation in methylenetetrahydrofolate reductase and 5-methyltetrahydrofolate-homocysteine methyltransferase in relation to breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 18:2453–2459
- Pooja S, Carlus J, Sekhar D et al (2015) MTHFR 677C > T polymorphism and the risk of breast cancer: evidence from an original study and pooled data for 28031 cases and 31880 controls. *PLoS One* 10:e0120654
- Prasad VVTS, Wilkhoo H (2011) Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. *Onkologie* 34:422–426
- Rai V (2014) The methylenetetrahydrofolate reductase C677T polymorphism and breast cancer risk in Asian populations. *Asian Pac J Cancer Prev* 15:5853–5860
- Ramos-Silva A, Figuera LE, Soto-Quintana OM et al (2015) Association of the C677T polymorphism in the methylenetetrahydrofolate reductase gene with breast cancer in a Mexican population. *Genet Mol Res* 14:4015–4026
- Sangrajrang S, Sato Y, Sakamoto H et al (2010) Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women. *Breast Cancer Res Treat* 123:885–893
- Sangrajrang S, Suleeporn S, Yasunori S et al (2009) Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. *Int J Cancer* 125:837–843
- Shrubsole MJ, Gao Y-T, Cai Q et al (2004) MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. *Cancer Epidemiol Biomarkers Prev* 13:190–196
- Stover P, Schirch V (1992) Enzymatic mechanism for the hydrolysis of 5,10-methylenetetrahydropteroylglutamate to 5-formyltetrahydropteroylglutamate by serine hydroxymethyltransferase. *Biochemistry* 31(7):2155–2164
- Suzuki T, Matsuo K, Hirose K et al (2008) One-carbon metabolism-related gene polymorphisms and risk of breast cancer. *Carcinogenesis* 29:356–362
- Tao MH, Shields PG, Nie J et al (2009) DNA promoter methylation in breast tumors: no association with genetic polymorphisms in MTHFR and MTR. *Cancer Epidemiol Biomarkers Prev* 18:998–1002
- Trinh BN, Ong CN, Coetzee GA et al (2002) Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. *Hum Genet* 111(3):299–302, **Epub 2002 Jul 26**

- Wang J, Jun W, Baocheng W et al (2010) The association between two polymorphisms in the TYMS gene and breast cancer risk: a meta-analysis. *Breast Cancer Res Treat* 128:203–209
- Weiner AS, Boyarskikh UA, Voronina EN et al (2012) Polymorphisms in the folate-metabolizing genes MTR, MTRR, and CBS and breast cancer risk. *Cancer Epidemiol* 36:e95–e100
- Weiwei Z, Liping C, Dequan L (2014) Association between dietary intake of folate, vitamin B6, B12 & MTHFR, MTR Genotype and breast cancer risk. *Pak J Med Sci* 30:106–110
- Wu X-Y, Ni J, Xu W-J et al (2012) Interactions between MTHFR C677T-A1298C variants and folic acid deficiency affect breast cancer risk in a Chinese population. *Asian Pac J Cancer Prev* 13:2199–2206
- Wu X, Zou T, Cao N et al (2014) Plasma homocysteine levels and genetic polymorphisms in folate metabolism are associated with breast cancer risk in Chinese women. *Hered Cancer Clin Pract* 12:2
- Xu X, Gammon MD, Zhang H et al (2007) Polymorphisms of one-carbon-metabolizing genes and risk of breast cancer in a population-based study. *Carcinogenesis* 28:1504–1509
- Yamada K, Chen Z, Rozen R, Matthews RG (2001) Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. *Proc Natl Acad Sci U S A* 98:14853–14858
- Yamada K, Gravel RA, Toraya T, Matthews RG (2006) Human methionine synthase reductase is a molecular chaperone for human methionine synthase. *Proc Natl Acad Sci U S A* 103(25):9476–9481
- Yu C-P, Wu M-H, Chou Y-C et al (2007) Breast cancer risk associated with multigenotypic polymorphisms in folate-metabolizing genes: a nested case-control study in Taiwan. *Anticancer Res* 27:1727–1732
- Yu L, Chen J (2012) Association of MTHFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: an update meta-analysis based on 51 research studies. *Diagn Pathol* 7:171
- Zhai X, Gao J, Hu Z et al (2006) Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis. *BMC Cancer* 6:138
- Zhong S, Xu J, Li W et al (2013) Methionine synthase A2756G polymorphism and breast cancer risk: an up-to-date meta-analysis. *Gene* 527: 510–515